13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

Page 2 of 9 – SEC Filing


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Sarissa Capital Management LP
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


(a)     ¨

(b)     ¨

3

SEC USE ONLY

4 SOURCE OF FUNDS

WC
5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

¨
6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

 

8

SHARED VOTING POWER

 

1,934,296 

9

SOLE DISPOSITIVE POWER

 

 

10

SHARED DISPOSITIVE POWER

 

1,934,296

11

AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 
1,934,296

12

CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

¨
13

PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

9.86%

14

TYPE
OF REPORTING PERSON

 

PN

 

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)